Development of PACAP38 analogue with improved stability: Physicochemical and in vitro/in vivo pharmacological characterization

Journal of Molecular Neuroscience

Volumn 43, Issue 1, 2011, Pages 85-93

  Onoue, Satomi ^a   Hanato, Junko ^a   Kuriyama, Kazuki ^a   Mizumoto, Takahiro ^b,c   Yamada, Shizuo ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b ILS Inc   (Japan)

^c American Peptide Company   (United States)

Author keywords

Apoptosis; Oxidative stress; PACAP; RIN m5F cells; Streptozotocin

Indexed keywords

HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; PROTEIN DERIVATIVE; STREPTOZOCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CHEMICAL MODIFICATION; CIRCULAR DICHROISM; CONTROLLED STUDY; DRUG DEGRADATION; DRUG STRUCTURE; DRUG SYNTHESIS; GLYCEMIC CONTROL; IN VITRO STUDY; IN VIVO STUDY; INSULINOMA; MALE; NONHUMAN; PHYSICAL CHEMISTRY; RAT; STREPTOZOCIN DIABETES; STRUCTURE ACTIVITY RELATION;

ANIMALS; CIRCULAR DICHROISM; DIABETES MELLITUS, EXPERIMENTAL; GLUCOSE TOLERANCE TEST; MALE; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; PROTEIN STABILITY; RATS; RATS, WISTAR;

RATTUS;

EID: 79951578398     PISSN: 08958696     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12031-010-9415-0     Document Type: Article

References (39)

1. B Ahren 2008 Role of pituitary adenylate cyclase-activating polypeptide in the pancreatic endocrine system Ann N Y Acad Sci 1144 28 35 1:CAS:528:DC%2BD1MXhtVajsbk%3D 10.1196/annals.1418.003 19076360
2. N Araki K Takagi 1992 Relaxant effect of pituitary adenylate cyclase-activating polypeptide on guinea-pig tracheal smooth muscle Eur J Pharmacol 216 113 117 1:CAS:528:DyaK38XksVSqsb0%3D 10.1016/0014-2999(92)90217-R 1326435
3. A Arimura 1998 Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems Jpn J Physiol 48 301 331 1:CAS:528:DyaK1MXlvFSq 10.2170/jjphysiol.48.301 9852340 (Pubitemid 28566695)
4. E Bonora 2008 Protection of pancreatic beta-cells: is it feasible? Nutr Metab Cardiovasc Dis 18 74 83 1:CAS:528:DC%2BD1cXivFWqtL0%3D 10.1016/j.numecd.2007.05.004 18096375 (Pubitemid 50020512)
5. S Bourgault D Vaudry B Botia A Couvineau M Laburthe H Vaudry A Fournier 2008 Novel stable PACAP analogs with potent activity towards the PAC1 receptor Peptides 29 919 932 1:CAS:528:DC%2BD1cXlvVClsLk%3D 10.1016/j.peptides.2008.01. 022 18353507
6. M Cnop N Welsh JC Jonas A Jorns S Lenzen DL Eizirik 2005 Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities Diabetes 54 Suppl 2 S97 S107 1:CAS:528:DC%2BD2MXht12gs7nF 10.2337/diabetes.54.suppl-2.S97 16306347 (Pubitemid 43343337)
7. DT Finegood MD McArthur D Kojwang MJ Thomas BG Topp T Leonard RE Buckingham 2001 Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death Diabetes 50 1021 1029 1:CAS:528:DC%2BD3MXkvFSgur0%3D 10.2337/diabetes.50.5.1021 11334404 (Pubitemid 32374532)
8. AF Gazdar WL Chick HK Oie HL Sims DL King GC Weir V Lauris 1980 Continuous, clonal, insulin- and somatostatin-secreting cell lines established from a transplantable rat islet cell tumor Proc Natl Acad Sci U S A 77 3519 3523 1:CAS:528:DyaL3cXkvFakurw%3D 10.1073/pnas.77.6.3519 6106192 (Pubitemid 10012266)
9. N Greenfield GD Fasman 1969 Computed circular dichroism spectra for the evaluation of protein conformation Biochemistry 8 4108 4116 1:CAS:528: DyaF1MXlt1SgtLk%3D 10.1021/bi00838a031 5346390
10. J Hanato K Kuriyama T Mizumoto K Debari J Hatanaka S Onoue S Yamada 2009 Liposomal formulations of glucagon-like peptide-1: improved bioavailability and anti-diabetic effect Int J Pharm 382 111 116 1:CAS:528:DC%2BD1MXhtlSltbbI 10.1016/j.ijpharm.2009.08.013 19698772
11. HE Hohmeier VV Tran G Chen R Gasa CB Newgard 2003 Inflammatory mechanisms in diabetes: lessons from the beta-cell Int J Obes Relat Metab Disord 27 Suppl 3 S12 S16 1:CAS:528:DC%2BD2cXls1Gn 10.1038/sj.ijo.0802493 14704737
12. H Inooka S Endo C Kitada E Mizuta M Fujino 1992 Pituitary adenylate cyclase activating polypeptide (PACAP) with 27 residues. Conformation determined by 1H NMR and CD spectroscopies and distance geometry in 25% methanol solution Int J Pept Protein Res 40 456 464 1:CAS:528:DyaK3sXjtlSrug%3D%3D 10.1111/j.1399-3011.1992.tb00324.x 1483839
13. H Inooka T Ohtaki O Kitahara T Ikegami S Endo C Kitada K Ogi H Onda M Fujino M Shirakawa 2001 Conformation of a peptide ligand bound to its G-protein coupled receptor Nat Struct Biol 8 161 165 1:CAS:528:DC%2BD3MXhtVShtbc%3D 10.1038/84159 11175907 (Pubitemid 32116070)
14. T Irako T Akamizu H Hosoda H Iwakura H Ariyasu K Tojo N Tajima K Kangawa 2006 Ghrelin prevents development of diabetes at adult age in streptozotocin-treated newborn rats Diabetologia 49 1264 1273 1:CAS:528:DC%2BD28Xktlaltbo%3D 10.1007/s00125-006-0226-3 16570155
15. K Kashimoto Y Nagano Y Suitani K Hamanaka T Mizumoto K Tomizaki H Takahata A Nagamoto A Ohata S Yoshihara T Ichimura 1996 Structure-activity relationship studies of PACAP-27 and VIP analogues Ann N Y Acad Sci 805 505 510 1:CAS:528:DyaK2sXhtVegtL8%3D 10.1111/j.1749-6632.1996.tb17511.x 8993431 (Pubitemid 27058048)
16. C Kitada A Sakiyama T Watanabe M Fujino 1991 Synthesis and structure-activity relationships of PACAP Pept Chem 1990 239 244
17. DY Kwon YS Kim IS Ahn S da Kim S Kang SM Hong S Park 2009 Exendin-4 potentiates insulinotropic action partly via increasing beta-cell proliferation and neogenesis and decreasing apoptosis in association with the attenuation of endoplasmic reticulum stress in islets of diabetic rats J Pharmacol Sci 111 361 371 1:CAS:528:DC%2BC3cXhs1OktQ%3D%3D 10.1254/jphs.09178FP 20019445
18. S Lenzen J Drinkgern M Tiedge 1996 Low antioxidant enzyme gene expression in pancreatic islets compared with various other mouse tissues Free Radic Biol Med 20 463 466 1:CAS:528:DyaK28XhvVWitLw%3D 10.1016/0891-5849(96)02051-5 8720919 (Pubitemid 26077870)
19. HM Liu XF Liu JL Yao CL Wang Y Yu R Wang 2006 Utilization of combined chemical modifications to enhance the blood-brain barrier permeability and pharmacological activity of endomorphin-1 J Pharmacol Exp Ther 319 308 316 1:CAS:528:DC%2BD28XhtVCksLrI 10.1124/jpet.106.106484 16803861 (Pubitemid 44455137)
20. RB Merrifield 1969 Solid-phase peptide synthesis Adv Enzymol Relat Areas Mol Biol 32 221 296 1:CAS:528:DyaF1MXks1OhtLg%3D 4307033
21. J Movassat B Portha 2007 Early administration of keratinocyte growth factor improves {beta}-cell regeneration in rat with streptozotocin-induced diabetes J Endocrinol 195 333 340 1:CAS:528:DC%2BD2sXhtlGms7rI 10.1677/JOE-07-0098 17951544 (Pubitemid 350143113)
22. M Nakata T Yada 2007 PACAP in the glucose and energy homeostasis: physiological role and therapeutic potential Curr Pharm Des 13 1105 1112 1:CAS:528:DC%2BD2sXmsFSiur0%3D 10.2174/138161207780618948 17430174 (Pubitemid 46739340)
23. S Naruse T Inoue T Mochizuki N Yanaihara 1992 Vasodilator action of guinea pig vasoactive intestinal polypeptide (VIP): comparison with common mammalian VIP Regul Pept 42 163 171 1:CAS:528:DyaK3sXlt1Kjuw%3D%3D 10.1016/0167-0115(92)90096-D 1289976 (Pubitemid 23000784)
24. Nokihara K, Ando E, Naruse S, Nakamura T, Wray V (1993) Highly efficient synthesis of PACAP and its related peptides and their biological actions in conscious dogs. In: Okada Y (ed) 31st Symposium on Peptide Chemistry. Protein Research Foundation, Osaka, Japan, Akashi, pp 265-268
25. S Onoue A Matsumoto Y Nagano K Ohshima Y Ohmori S Yamada R Kimura T Yajima K Kashimoto 2004 Alpha-helical structure in the C-terminus of vasoactive intestinal peptide: functional and structural consequences Eur J Pharmacol 485 307 316 1:CAS:528:DC%2BD2cXnvVygtA%3D%3D 10.1016/j.ejphar.2003.11.046 14757155 (Pubitemid 38134429)
26. S Onoue S Yamada T Yajima 2007 Bioactive analogues and drug delivery systems of vasoactive intestinal peptide (VIP) for the treatment of asthma/COPD Peptides 28 1640 1650 1:CAS:528:DC%2BD2sXhtVWms7nM 10.1016/j.peptides.2007.04. 009 17537541 (Pubitemid 47361420)
27. S Onoue J Hanato S Yamada 2008 Pituitary adenylate cyclase-activating polypeptide attenuates streptozotocin-induced apoptotic death of RIN-m5F cells through regulation of Bcl-2 family protein mRNA expression FEBS J 275 5542 5551 1:CAS:528:DC%2BD1cXhsVWkt77O 18959742
28. S Onoue S Misaka S Yamada 2008 Structure-activity relationship of vasoactive intestinal peptide (VIP): potent agonists and potential clinical applications Naunyn Schmiedebergs Arch Pharmacol 377 579 590 1:CAS:528:DC%2BD1cXnsVSqtrg%3D 10.1007/s00210-007-0232-0 18172612
29. S Onoue S Misaka Y Ohmori H Sato T Mizumoto M Hirose S Iwasa T Yajima S Yamada 2009 Physicochemical and pharmacological characterization of novel vasoactive intestinal peptide derivatives with improved stability Eur J Pharm Biopharm 73 95 101 1:CAS:528:DC%2BD1MXpvFygtbo%3D 10.1016/j.ejpb.2009.05.013 19481602
30. B Portha C Levacher L Picon G Rosselin 1974 Diabetogenic effect of streptozotocin in the rat during the perinatal period Diabetes 23 889 895 1:CAS:528:DyaE2MXntFWrsg%3D%3D 4279194
31. B Portha O Blondel P Serradas R McEvoy MH Giroix M Kergoat D Bailbe 1989 The rat models of non-insulin dependent diabetes induced by neonatal streptozotocin Diabete Metab 15 61 75 1:CAS:528:DyaL1MXmtFalsrY%3D 2525491 (Pubitemid 19140020)
32. MF Powell T Stewart L Otvos Jr L Urge FC Gaeta A Sette T Arrhenius D Thomson K Soda SM Colon 1993 Peptide stability in drug development. II. Effect of single amino acid substitution and glycosylation on peptide reactivity in human serum Pharm Res 10 1268 1273 1:CAS:528:DyaK3sXmslymsLY%3D 10.1023/A:1018953309913 8234161 (Pubitemid 23261824)
33. R Riachy B Vandewalle J Kerr Conte E Moerman P Sacchetti B Lukowiak V Gmyr T Bouckenooghe M Dubois F Pattou 2002 1, 25-Dihydroxyvitamin D3 protects RINm5F and human islet cells against cytokine-induced apoptosis: implication of the antiapoptotic protein A20 Endocrinology 143 4809 4819 1:CAS:528: DC%2BD38Xpt1eltL0%3D 10.1210/en.2002-220449 12446608 (Pubitemid 35397621)
34. RP Robertson JS Harmon 2006 Diabetes, glucose toxicity, and oxidative stress: a case of double jeopardy for the pancreatic islet beta cell Free Radic Biol Med 41 177 184 1:CAS:528:DC%2BD28Xmt1OrsLw%3D 10.1016/j.freeradbiomed.2005. 04.030 16814095 (Pubitemid 43928495)
35. Sakiyama A, Kitada C, Watanabe T, Masuda Y, Fujino M (1991) Structure-activity relationship of pituitary adenylate cyclase activating polypeptide (PACAP). In: Suzuki A (ed) Japanese Peptide Symposium. Protein Research Foundation, Osaka, pp 215-220
36. C Tourrel D Bailbe MJ Meile M Kergoat B Portha 2001 Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age Diabetes 50 1562 1570 1:CAS:528:DC%2BD3MXltVWiuro%3D 10.2337/diabetes.50.7. 1562 11423477 (Pubitemid 33639596)
37. GL Wilson PC Hartig NJ Patton SP LeDoux 1988 Mechanisms of nitrosourea-induced beta-cell damage. Activation of poly (ADP-ribose) synthetase and cellular distribution Diabetes 37 213 216 1:CAS:528:DyaL1cXht1Kisbo%3D 10.2337/diabetes.37.2.213 2968935 (Pubitemid 18066607)
38. V Wray C Kakoschke K Nokihara S Naruse 1993 Solution structure of pituitary adenylate cyclase activating polypeptide by nuclear magnetic resonance spectroscopy Biochemistry 32 5832 5841 1:CAS:528:DyaK3sXktVWisb0%3D 10.1021/bi00073a016 8504103 (Pubitemid 23175686)
39. V Wray K Nokihara S Naruse 1998 Solution structure comparison of the VIP/PACAP family of peptides by NMR spectroscopy Ann N Y Acad Sci 865 37 44 1:CAS:528:DyaK1MXmvFWnsA%3D%3D 10.1111/j.1749-6632.1998.tb11160.x 9927994 (Pubitemid 29047809)